Here is why Inovio Pharmaceuticals (INO) is rising after hours
- Inovio Pharmaceuticals has spiked this year for one reason, it’s COVID-19 program.
- The company was conducting a phase 2 clinical study of an experimental MERS vaccine even before the novel coronavirus that causes COVID-19.
- Their pipeline candidate VGX-3100 is further along than most of the competition, last month Inovio announced positive interim results from two mid-stage clinical studies evaluating the drug in treating anal dysplasia and vulvar dysplasia, two precancerous conditions caused by human papillomavirus (HPV) types 16 and 18.
- The company should report results from a late-stage study of VGX-3100 in treating cervical dysplasia later in 2020.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm’s drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.